BioSpace News Archive

Urica Therapeutics, Inc., a Fortress Biotech, Inc. subsidiary company focused on the development and commercialization of pharmaceutical products to treat gout and other conditions associated with hyperuricemia, announced that the Company has expanded its exclusive license agreement with Fuji Yakuhin Co. Ltd. for the development of dotinurad to include the Middle East and North Africa and Turkey territories.

Vifor Pharma AG announced that the Commercial Court St. Gallen has cancelled all remaining publicly held registered shares of Vifor with a nominal value of CHF 0.01 each.

IRLAB Therapeutics AB announced that the final patient has completed the treatment period and follow-up visit in the Phase IIb study of mesdopetam in levodopa-induced dyskinesia in people with Parkinson’s disease.

PrecisionLife Limited, a global techbio company generating the deepest insights into disease biology to create novel precision medicines in chronic diseases announced that it has entered into a multi-target discovery and validation partnership with Ono Pharmaceutical Co., Ltd., an R&D-orientated pharmaceutical company.

Ellipses Pharma, a global drug development company focused on accelerating the development of new oncology treatments, announces the first dosing of a patient in EP0031-101, a trial investigating Ellipses’ next generation selective RET inhibitor EP0031.

Eli Lilly and Company and EVA Pharma announced a collaboration to deliver a sustainable supply of high-quality, affordable human and analogue insulin to at least one million people living with type 1 and type 2 diabetes in low- to middle-income countries, most of which are in Africa.

Tiziana Life Sciences Ltd. announced that it has received a notification letter from Nasdaq Stock Market LLC that the Company has been granted an additional 180-day compliance period, with a new deadline of June 12, 2023, to regain compliance with Nasdaq’s minimum bid price rule.

Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail, Amarin’s president and chief executive officer, is scheduled to participate at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023.

Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that members of its Executive Management Team are scheduled to present at the Goldman Sachs CEOs Unscripted Conference on Thursday, January 5, 2023, at 11:25 a.m. ET and at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 3:45 p.m. PT / 6:45 p.m. ET.

Kymera Therapeutics, Inc. (NASDAQ: KYMR) today announced positive clinical results from the patient cohort portion of its KT-474 (IRAK4) Phase 1 clinical trial, as well as updates on its three oncology programs: KT-413 (IRAKIMiD), KT-333 (STAT3) and KT-253 (MDM2).